Zobrazeno 1 - 10 of 29 pro vyhledávání: '"Lionel Bosquée"'
1
Akademický článek
Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT).
Autor: Jacques De Grève, Jan Van Meerbeeck, Johan F Vansteenkiste, Lore Decoster, Anne-Pascale Meert, Peter Vuylsteke, Christian Focan, Jean-Luc Canon, Yves Humblet, Guy Berchem, Benoit Colinet, Danny Galdermans, Lionel Bosquée, Joanna Vermeij, Alex Dewaele, Caroline Geers, Denis Schallier, Erik Teugels
Publikováno v: PLoS ONE, Vol 11, Iss 3, p e0147599 (2016)
INTRODUCTION:Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibition is the preferred first-line treatment of advanced adenocarcinoma of the lung that harbors EGFR activating tyrosine kinase domain mutations. Most data available pertain to
Externí odkaz: https://doaj.org/article/d77d90c2874a41ca9219fe0d09d1012a
Zobrazit plný text záznamu
3
An Open-Label, Multicenter, Randomized, Phase II Study of Pazopanib in Combination with Pemetrexed in First-Line Treatment of Patients with Advanced-Stage Non–Small-Cell Lung Cancer
Autor: Martin Reck, Elaine M. Paul, Pilar Lianes-Barragán, Christos Chouaid, Entisar Sigal, Joachim von Pawel, T. LeChevalier, Giorgio V. Scagliotti, Anders Mellemgaard, Benjamin Besse, Lionel Bosquée, Rodrigo Ruiz-Soto, Enriqueta Felip, Lone Ottesen
Publikováno v: Journal of Thoracic Oncology. 8:1529-1537
Introduction: This randomized open-label phase II study evaluated the efficacy, safety, and tolerability of pazopanib in combination with pemetrexed compared with the standard cisplatin/pemetrexed doublet in patients with previously untreated, advanc
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5c401de0c901f9643c49cd9f7734288
https://doi.org/10.1097/jto.0000000000000005
Zobrazit plný text záznamu
5
Soluble Mesothelin, Megakaryocyte Potentiating Factor, and Osteopontin as Markers of Patient Response and Outcome in Mesothelioma
Autor: Paul Germonpré, Robert Gosselin, Lionel Bosquée, Yoshiro Kishi, Jan P. van Meerbeeck, Paul De Vuyst, Kristiaan Nackaerts, Eliane Kellen, Walter De Wever, Joris R. Delanghe, Kevin Hollevoet, Catherine Legrand
Publikováno v: Journal of thoracic oncology
Introduction: Soluble mesothelin (SM), megakaryocyte potentiating factor (MPF), and osteopontin (OPN) are blood biomarkers of mesothelioma. This study evaluates their use as markers of response to therapy and outcome. Methods: Sixty-two patients with
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64d2f57b04f68e4c413f6a79d421799e
https://doi.org/10.1097/jto.0b013e3182272294
Zobrazit plný text záznamu
7
Thrombo-embolic events in cancer patients with impaired renal function
Autor: Stéphane Holbrechts, Lionel Duck, Jean-Luc Canon, Lionel Bosquée, Jean Francois Baurain, Kristin Jochmans, Ismail Elalamy, Alain Bols, Michel Peeters, Jeroen Mebis, Willem Lybaert, Joëlle Nortier, Paul Clement, Ahmad Awada
Publikováno v: Journal of blood disorders & transfusion, 5 (4
Venous Thromboembolism (VTE) is a frequent cause of mortality and morbidity in patients with malignancy. Thrombosis is one of the leading causes of death in patients with malignancy after cancer itself. As such, prompt recognition and treatment of VT
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79f9de0ec4793ba5be68b7dd3c96eb01
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/199342
Zobrazit plný text záznamu
9
The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor
Autor: Lionel Bosquée, Eliane Kellen, Yoshiro Kishi, Jan P. van Meerbeeck, Paul Germonpré, Kristiaan Nackaerts, Joris R. Delanghe, Kevin Hollevoet, Paul De Vuyst, Olivier Thas, Catherine Legrand, J. Thimpont
Publikováno v: Chest, Vol. 141, no. 2, p. 477-484 (2012)
Chest
Background: Soluble mesothelin (SM) and megakaryocyte potentiating factor (MPF) are serum biomarkers of mesothelioma. This study examined the effect of clinical covariates on biomarkers levels and their diagnostic and prognostic value. Methods: Five
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b3b4e56696f524df8f11184e4634fd6
https://hdl.handle.net/2078.1/127126
Zobrazit plný text záznamu
10
Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma
Autor: Eliane Kellen, Joris R. Delanghe, Jan P. van Meerbeeck, Catherine Legrand, Paul Germonpré, Yoshiro Kishi, Lionel Bosquée, J. Thimpont, Kevin Hollevoet, Paul De Vuyst, Kristiaan Nackaerts
Publikováno v: American journal of respiratory and critical care medicine
Rationale: Soluble mesothelin (SM) is currently the reference serum biomarker of malignant pleural mesothelioma (MPM). Megakaryocyte potentiating factor (MPF), which originates from the same precursor protein, is potentially more sensitive, yet lacks
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::146e2f31c264cf003ecd9c5be37f27aa
https://pubmed.ncbi.nlm.nih.gov/20075387
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje